Eculizumab
- PDF / 139,563 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 92 Downloads / 138 Views
1
Eculizumab Vomiting and nausea: case report A 50-year-old woman received four doses of IV eculizumab 900mg once weekly for atypical haemolytic uraemic syndrome. She then received two doses of eculizumab 1200mg every 2 weeks, but developed nausea and vomiting. She refused her next dose of eculizumab. The dose was delayed by 1 day and was decreased to 600mg weekly for nine more doses. The dose was then decreased to 600mg every 2 weeks. [Patient outcome not stated.] Ohanian M, et al. Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): An update on a previous case report. Clinical Pharmacology: Advances and Applications 3: 45-50, No. 1, Nov 2011 803066666 USA
0114-9954/10/1387-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 4 Feb 2012 No. 1387
Data Loading...
